Takeda
Takeda’s Ninlaro extends myeloma survival in trial
December 7, 2015Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma
Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …
Takeda reveals five-year Adcetris survival data
December 6, 2015Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology
Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
Clinigen launches UK managed access program for Takeda’s ixazomib
November 30, 2015Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology
Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …
Challenges in oncology R&D – part 2
November 25, 2015Manufacturing and Production, Research and Development R&D, Takeda, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
FDA approves Takeda’s Ninlaro for multiple myeloma
November 23, 2015Manufacturing and Production, Research and Development Takeda, myeloma
The US Food and Drug Administration (FDA) has approved Takeda’s Ninlaro (ixazomib) for use in combination with lenalidomide and dexamethasone …
Top five pharma controversies of 2015 (so far)
November 20, 2015Medical Communications, Sales and Marketing AstraZeneca, Martin Shkreli, Philidore, Takeda, Turing Pharmaceutical, Valeant, Warner Chilcott, controversies, fraud, reputation, tax avoidance, turing
5. AstraZeneca forced to deny tax avoidance allegations
Challenges in oncology R&D
November 18, 2015Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
Mayor of London announces Takeda, UCL R&D partnership
October 14, 2015Research and Development London, R&D, Takeda, UCL, neurology
Takeda is teaming up with researchers at University College London (UCL) to identify and validate novel target genes for the …
Takeda in Velcade patent blow
August 25, 2015Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …
Takeda gets European MAA approval for ixazomib
August 21, 2015Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma
Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …
Orexigen and Takeda reboot Contrave collaboration
August 12, 2015Research and Development Contrave, FDA, Takeda, orexigen, weight loss drugs
Orexigen has agreed to foot the $200 million bill for a new trial to prove its claims that Contrave, the …
Takeda cancer drug gets EMA boost
July 29, 2015Research and Development, Sales and Marketing Takeda, ixazomib, multiple myeloma
The EMA has granted Takeda an accelerated assessment for its multiple myeloma drug, ixazomib. The Agency’s Committee for Medicinal Products …
NICE u-turns on Entyvio for Crohn’s disease
July 10, 2015Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding
NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …
Adam Zaeske appointed as managing director of Takeda UK and Ireland
July 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adam Zaeske, Takeda
Japanese pharma firm Takeda has appointed Adam Zaeske as managing director of Takeda UK and Ireland.Zaeske has been with Takeda …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
